Common questions about Efferalgan 150mg (FAQ)
Q: How is Efferalgan 150mg different from other paracetamol products available?
Official product information indicates that Efferalgan 150mg is distinct due to its formulation, typically supplied as an effervescent powder or suppository. These specific forms are created to suit the needs of the pediatric population. The 150mg strength is designed for precise, proportional dosing based on the child's body weight as defined by regulatory protocols.
Q: What specific types of pain is this medicine indicated to treat?
The active ingredient is officially indicated for the general symptomatic relief of fever and episodes of mild to moderate acute pain. This typically includes common discomforts like minor headache, toothache, and general aches associated with common cold symptoms. Regulatory information and available studies describe how symptoms change across short-term use.
Q: Does the 150mg formulation work differently than a higher strength like 500mg?
The core active ingredient and its fundamental mechanism of action are considered the same, regardless of the dose unit. The different strengths represent an administrative difference designed to facilitate the exact proportional mg/ kg dosing required for the pediatric patient group.
Q: Why is Efferalgan 150mg available in a suppository or effervescent powder form?
Regulatory documents explain that these forms are primarily chosen to make the medicine easier to administer to children. The suppository form can be beneficial in situations where a child is unable to swallow an oral medication or when they are experiencing vomiting.
Q: How long does it typically take for Efferalgan 150mg to start reducing a fever?
According to regulatory pharmacokinetic data, the active ingredient typically begins to reach its maximum concentration in the bloodstream within 30 minutes to 1 hour after being taken orally. This time frame generally aligns with when the fever-reducing effect may begin.
Q: What is the expected duration of effect after a single dose?
The regulatory guidelines for safe administration require a minimum time interval of at least 6 hours between doses for those with normal kidney function. The mandated interval is established based on the time required to safely clear the medicine from the system, which informs the expected duration of the effect.
Q: Are there any foods or drinks that should be avoided when giving this medicine?
Regulatory information advises against use with chronic alcohol consumption due to the increased risk of liver damage. Official documents also note that while certain foods do not need to be strictly avoided, taking the medicine with food may delay its absorption and the onset of its effect.
Q: What is the reason for the minimum time interval required between administrations?
The mandated minimum interval of at least 6 hours is put in place by regulatory bodies to ensure that the drug has sufficient time to be processed and cleared from the body. Adhering to this timing is necessary to avoid exceeding the maximum daily dose, as cumulative high doses carry a substantial risk of liver toxicity.
Q: Does using the suppository route change how quickly the medicine is absorbed?
According to regulatory pharmacokinetic studies, the absorption rate of the active ingredient varies depending on the route of administration. Rectal administration (suppository) is generally described as being slower and more variable compared to the absorption achieved through the oral route (effervescent powder).
Q: What physical signs should a parent look for to know the medicine is starting to work?
Official information states that the medicine works to reduce temperature and alleviate discomfort. Observable signs that the medicine is starting to work are consistent with symptom improvement, such as the child appearing more settled, less irritable, or resting comfortably, which indicates a reduction in pain or fever.
Q: What are the most commonly reported side effects of paracetamol in children?
Regulatory safety documents primarily classify the reported adverse reactions as rare or very rare. When this medicine is used strictly according to the recommended dose and intervals, official information indicates that common adverse events are limited or are not consistently classified in regulatory lists.
Q: What are the potential signs of a serious allergic reaction to Efferalgan 150mg?
Official product warnings highlight the potential for severe hypersensitivity reactions, including anaphylaxis and angioedema (swelling beneath the skin). Signs that may be observed in such severe reactions can include swelling of the face, throat, or tongue, and difficulty breathing.
Q: Can paracetamol potentially cause stomach upset or digestive issues?
While the adverse reaction profile lists some gastrointestinal issues, such as the very rare occurrence of pancreatitis, general stomach upset is not typically classified as a common side effect for this medicine in regulatory documents, unlike other classes of pain relievers.
Q: Does Efferalgan 150mg typically cause drowsiness or sleepiness?
The regulatory profile of this medicine, which details expected and reported side effects, typically does not list drowsiness or sedation as an adverse reaction.
Q: What are the non-specific warning signs associated with paracetamol overdose?
According to regulatory documents, early signs that may indicate an overdose include non-specific symptoms such as nausea, vomiting, loss of appetite, and abdominal pain. These symptoms, which may precede signs of serious liver damage, should be immediately reported to a healthcare professional.
Q: What is the potential long-term risk associated with taking paracetamol for many days?
Official regulatory warnings caution against prolonged or repeated use of the active ingredient without medical supervision. Regulatory warnings indicate this is due to the potential risk of renal (kidney) toxicity and the risk of severe liver damage associated with cumulative high doses.
Q: Can Efferalgan 150mg be used in children who have a known kidney condition?
Regulatory documents advise caution when the medicine is used in patients with existing renal (kidney) impairment. For severe kidney conditions, the official guidelines mandate that the minimum interval between doses must be extended to at least 8 hours to ensure the medicine is cleared safely.
Q: Are there specific warnings for individuals with G6PD deficiency?
Official regulatory warnings advise caution when administering this medicine to individuals diagnosed with Glucose-6-phosphate dehydrogenase (G6PD) deficiency. This is due to the potential risk of haemolytic anemia, which is a condition involving the destruction of red blood cells.
Q: What is the reason the suppository form is not recommended for children with diarrhea?
The suppository form is officially discouraged for use when a child is experiencing diarrhea. This is due to regulatory concerns that the diarrhea may impair the retention of the suppository and therefore reduce the absorption of the active ingredient, potentially making the dose less effective.
Q: Is this medicine known by a different generic or brand name in countries like the US?
The active substance in this medicine, Paracetamol, is widely known as Acetaminophen in other countries, including the United States. This generic substance is then sold under various brand names globally.
Q: What types of other medicines commonly contain paracetamol as an active ingredient?
Regulatory sources specifically warn against using this medicine concurrently with combination cold, cough, and flu products. This is because these common over-the-counter medicines frequently contain the same active ingredient, Paracetamol, which can unintentionally increase the risk of accidental overdose.
Q: Can I safely give my child Efferalgan 150mg if they are also taking cold medication?
Official regulatory warnings strictly state that concomitant use of other products containing paracetamol must be avoided. Official warnings emphasize avoiding co-administration to ensure the maximum safe daily limit is not exceeded, given the associated risk of severe toxicity.
Q: Does Efferalgan 150mg interact with any commonly prescribed antibiotics?
Regulatory documents mention specific interactions with the antibiotic Flucloxacillin. Official warnings note that using these two medicines together is associated with an increased risk of high anion gap metabolic acidosis (HAGMA) in individuals with specific risk factors.
